Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 ...
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAPClears the way to ...
Biodexa Pharmaceuticals announces outcome of a Type C meeting with FDA on eRapa
Biodexa Pharmaceuticals (BDRX) announced the results of its Type C meeting with the U.S. Food and Drug Administration, FDA, regarding the ...